Apellis Pharmaceuticals (APLS) News Today $17.76 0.00 (0.00%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$17.77 +0.01 (+0.06%) As of 06/18/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period David O. Watson Sells 5,000 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockJune 19 at 7:48 AM | insidertrades.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells 5,000 SharesApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) General Counsel David O. Watson sold 5,000 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $18.77, for a total transaction of $93,850.00. Following the completion of the transaction, the general counsel now owns 133,730 shares in the company, valued at approximately $2,510,112.10. This trade represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.June 18 at 11:23 AM | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Assenagon Asset Management S.A.Assenagon Asset Management S.A. grew its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 147.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,325 shareJune 18 at 3:39 AM | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.4% - What's Next?Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 3.4% - Here's What HappenedJune 16 at 2:16 PM | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of "Moderate Buy" from AnalystsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-one analysts that are covering the stock, Marketbeat reports. Nine analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has gJune 14, 2025 | marketbeat.comSG Americas Securities LLC Grows Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)SG Americas Securities LLC raised its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 2,004.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 366,144 shares of the company's stock after acquiringJune 12, 2025 | marketbeat.comCantor Fitzgerald Weighs in on APLS FY2026 EarningsJune 12, 2025 | americanbankingnews.comPallas Capital Advisors LLC Grows Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Pallas Capital Advisors LLC raised its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 218.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,534 shares of the cJune 11, 2025 | marketbeat.comEquities Analysts Offer Predictions for APLS FY2026 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Apellis Pharmaceuticals in a report released on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the company will earnJune 10, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Merit Financial Group LLCMerit Financial Group LLC lifted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 324.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 33,762 shares of the company's stock afJune 9, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Has $1.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 140.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,594 shares of the coJune 9, 2025 | marketbeat.comApellis, Sobi present data from open-label period of Phase 3 VALIANT studyJune 7, 2025 | finance.yahoo.comHennion & Walsh Asset Management Inc. Grows Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 48.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,166 shares of the compaJune 7, 2025 | marketbeat.comApellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGNJune 6, 2025 | globenewswire.comApellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | globenewswire.comApellis Pharmaceuticals (NASDAQ:APLS) Trading Up 7.7% Following Analyst UpgradeApellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 7.7% Following Analyst UpgradeJune 3, 2025 | marketbeat.comWhy Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On MondayJune 3, 2025 | msn.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $29.00Wells Fargo & Company increased their price target on shares of Apellis Pharmaceuticals from $26.00 to $29.00 and gave the stock an "equal weight" rating in a report on Monday.June 2, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 11.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional invJune 2, 2025 | marketbeat.comWhat is Zacks Research's Forecast for APLS Q2 Earnings?Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Stock analysts at Zacks Research reduced their Q2 2025 earnings estimates for Apellis Pharmaceuticals in a research note issued on Tuesday, May 27th. Zacks Research analyst R. Department now forecasts that the company will earn ($0.46) pMay 31, 2025 | marketbeat.comToronto Dominion Bank Has $31.82 Million Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Toronto Dominion Bank lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 3,791.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 997,053 shares oMay 28, 2025 | marketbeat.comVoloridge Investment Management LLC Reduces Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Voloridge Investment Management LLC lessened its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 57.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 345,885 shares of the company's stock after selling 4May 27, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Squarepoint Ops LLCSquarepoint Ops LLC boosted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 84.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 166,962 shares of the company's stock after purchasing an additional 76,621 shares during the period. SquaMay 27, 2025 | marketbeat.comNuveen Asset Management LLC Has $15.67 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Nuveen Asset Management LLC raised its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 44.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 491,107 shares of the company's stock after buying an additional 150,384May 27, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Man Group plcMan Group plc boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 194.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,292 shares of the company's stock after purchasing an additional 32,55May 26, 2025 | marketbeat.comRoyal Bank of Canada Acquires 1,376,832 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Royal Bank of Canada lifted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 969.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,518,827 sharesMay 24, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-one analysts that are currently covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating, eleven hMay 22, 2025 | marketbeat.comToronto Dominion Bank Purchases 971,431 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Toronto Dominion Bank raised its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 3,791.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 997,053 shares of the company's stock after acquiring an additional 971,4May 21, 2025 | marketbeat.comGotham Asset Management LLC Purchases New Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Gotham Asset Management LLC acquired a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 24,299 shares of the company's stock, valued at approxiMay 21, 2025 | marketbeat.comApellis Pharmaceuticals: Have Some PatienceMay 20, 2025 | seekingalpha.comRafferty Asset Management LLC Has $7.71 Million Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Rafferty Asset Management LLC boosted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 18.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 241,474 shares of the coMay 20, 2025 | marketbeat.com793,187 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Purchased by Suvretta Capital Management LLCSuvretta Capital Management LLC acquired a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 793,187 shares of tMay 19, 2025 | marketbeat.comPoint72 Asset Management L.P. Invests $40.46 Million in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Point72 Asset Management L.P. purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,267,958 shares of the cMay 18, 2025 | marketbeat.comPoint72 Europe London LLP Buys Shares of 192,694 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Point72 Europe London LLP purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 192,694 shares of the company's stock, valued at approximately $6,149,000. Point72 EuropeMay 17, 2025 | marketbeat.comPolar Capital Holdings Plc Grows Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Polar Capital Holdings Plc grew its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 45.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,577,175 shares of the company's sMay 17, 2025 | marketbeat.comNorthern Trust Corp Has $17.46 Million Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Northern Trust Corp lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 20.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 547,276 shares of the company's stock afteMay 17, 2025 | marketbeat.comBank of America Corp DE Has $53.62 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Bank of America Corp DE increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 72.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,680,213 shares of the company's stock aMay 16, 2025 | marketbeat.comAmeriprise Financial Inc. Boosts Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Ameriprise Financial Inc. boosted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 882,801 shares of the company's stockMay 16, 2025 | marketbeat.comDeutsche Bank AG Has $56.75 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Deutsche Bank AG boosted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 1.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,778,377 shares of the company's stock after purchasing an addiMay 15, 2025 | marketbeat.comBaird Financial Group Inc. Grows Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Baird Financial Group Inc. grew its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 101.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,665 shares of the compMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Acquires New Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Integral Health Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 420,000 shares of theMay 14, 2025 | marketbeat.comHudson Bay Capital Management LP Buys 85,000 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Hudson Bay Capital Management LP increased its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 32.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 345,000 shares of theMay 14, 2025 | marketbeat.comCantor Fitzgerald Has Negative View of APLS FY2025 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will post earningMay 13, 2025 | marketbeat.comHC Wainwright Has Negative Estimate for APLS Q2 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at HC Wainwright lowered their Q2 2025 EPS estimates for Apellis Pharmaceuticals in a research note issued on Thursday, May 8th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.49) per shareMay 13, 2025 | marketbeat.comWedbush Cuts Earnings Estimates for Apellis PharmaceuticalsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at Wedbush reduced their Q2 2025 earnings estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 7th. Wedbush analyst L. Chico now expects that the compaMay 13, 2025 | marketbeat.comWilliam Blair Issues Pessimistic Forecast for APLS EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at William Blair decreased their Q2 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research note issued on Wednesday, May 7th. William Blair analyst L. Hanbury-Brown now forecasts that theMay 13, 2025 | marketbeat.comWells Fargo & Company MN Sells 133,752 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Wells Fargo & Company MN lessened its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 96.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,616 shares of the company's stock after selling 133,752 shareMay 12, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Downgraded to "Outperform" Rating by Raymond JamesRaymond James cut Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and set a $52.00 target price for the company. in a report on Friday.May 11, 2025 | marketbeat.comBank of America Downgrades Apellis Pharmaceuticals (NASDAQ:APLS) to NeutralBank of America lowered shares of Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and set a $23.00 price target for the company. in a report on Friday.May 11, 2025 | marketbeat.comCubist Systematic Strategies LLC Invests $6.12 Million in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Cubist Systematic Strategies LLC acquired a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 191,687 shares of the company's stock, valMay 11, 2025 | marketbeat.com Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Media Mentions By Week APLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼0.880.69▲Average Medical News Sentiment APLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼59▲APLS Articles Average Week Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BPMC News BBIO News ROIV News VRNA News RVMD News ELAN News LEGN News GRFS News TLX News TGTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 6/19/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APLS Stock Free APLS Stock Alerts